



Origin BioMed Awarded Red Herring Top 100 Global Company

Halifax-based consumer health products company recognized as a world technology leader

January 26, Halifax – Origin BioMed Inc., a privately-held Canadian consumer health products company, today announced that it has been awarded as one of the Red Herring [Top 100 Global Companies](#).

Red Herring Top 100 Global Companies are chosen from winners and finalists of the previous competitions for North America, Europe and Asia Red Herring Top 100 Companies. Out of 1,800 successful and highly eligible companies, the Red Herring editorial team deployed a detailed process to drill-down the best companies first to 200 finalists, then to the top 100 winners of this global award. Evaluations were made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration.

The announcement of the winners was made at the Red Herring 100 Global taking place in San Diego from January 14-16, 2009. Present among the finalists were elite executives and venture capital leaders from around the world.

“We were so pleased to announce Origin BioMed Inc. as a Red Herring Top 100 Global Company,” commented Red Herring publisher Alex Vieux. “Origin BioMed has proven to be a company excelling in their industry and its ripples have turned into waves. It was difficult for us to narrow down, but we are pleased to have included Origin BioMed in our list of promising companies. We look forward to the changes it makes to the non-prescription drug industry in the future.” Origin was one of only 4 Canadian companies to receive the Award, with companies from 25 other countries also receiving the award.

“Since its inception, Origin’s mission has been to leverage cutting edge technology to bring scientifically proven natural products to professional care givers and consumers. We strive to increase over-the-counter treatment options for nerve pain, and Red Herring’s recognition demonstrates that our model has begun to position us as a global leader in our field,” said Robert Cervelli, President and CEO, Origin BioMed. “It was a real honour to accept this award on behalf of the entire dynamic team at Origin,” he added.

Origin BioMed’s leading drug product, Neuragen[®], is the first non-prescription topical treatment for rapid relief of diabetic and post-shingles nerve pain. Neuragen[®] is available in all leading pharmacies in Canada and the United States.

About Origin BioMed Inc.

Origin BioMed, Inc. is a privately-held Canadian consumer health products company with business operations throughout the U.S. and Canada. Headquartered in Halifax, Nova Scotia, Origin BioMed Inc. manufactures health products with the highest quality active ingredients, at therapeutic levels, with evidence of scientific or clinical efficacy since 2001. Its leading drug product, Neuragen[®], helps relieve pain caused by diabetic nerve damage. For more information, please visit: www.originbiomed.com or www.neuragen.com.

Contact:

Robert Silverstein

VP Operations

902-444-8696

silverstein@originbiomed.com

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available on the Internet at www.redherring.com.

Anam Alpenia

Red Herring, Inc.

Phone: 650-428-2900

Email: aalpenia@redherring.com